NuCana plc is a clinical-stage biopharmaceutical company dedicated to enhancing cancer treatments through its ProTide technology. This innovative approach transforms conventional chemotherapy agents, ...
NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment. In premarket trading ADRs were up $2.44 to $4.98. However ...
As of June 30, 2024, NuCana had cash and cash equivalents of $15.3 million, which is expected to provide a cash runway into Q1 2025. While there were prognostic imbalances favoring the control arm ...
Seven of the 12 patients had a progression-free survival time of over five months. Hugh Griffith, NuCana's Founder and CEO, said, "We are very excited to share these data on NUC-7738 in ...
As of 08:01 CEST. Market open. On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's ...